Development of recombinant rotavirus carrying herpes simplex virus 2 glycoprotein D gene based on reverse genetics technology

Microbiol Immunol. 2024 Feb;68(2):56-64. doi: 10.1111/1348-0421.13107. Epub 2023 Dec 14.

Abstract

Vaccine development for herpes simplex virus 2 (HSV-2) has been attempted, but no vaccines are yet available. A plasmid-based reverse genetics system for Rotavirus (RV), which can cause gastroenteritis, allows the generation of recombinant RV containing foreign genes. In this study, we sought to develop simian RV (SA11) as a vector to express HSV-2 glycoprotein D (gD2) and evaluated its immunogenicity in mice. We generated the recombinant SA11-gD2 virus (rSA11-gD2) and confirmed its ability to express gD2 in vitro. The virus was orally inoculated into suckling BALB/c mice and into 8-week-old mice. Serum IgG and IgA titers against RV and gD2 were measured by ELISA. In the 8-week-old mice inoculated with rSA11-gD2, significant increases in not only antibodies against RV but also IgG against gD2 were demonstrated. In the suckling mice, antibodies against RV were induced, but gD2 antibody was not detected. Diarrhea observed after the first inoculation of rSA11-gD2 in suckling mice was similar to that induced by the parent virus. A gD2 expressing simian RV recombinant, which was orally inoculated, induced IgG against gD2. This strategy holds possibility for genital herpes vaccine development.

Keywords: genital herpes; herpes simplex virus 2; reverse genetics; rotavirus; vaccine.

MeSH terms

  • Animals
  • Antibodies, Viral
  • Glycoproteins / genetics
  • Herpes Genitalis*
  • Herpesvirus 2, Human / genetics
  • Immunoglobulin G
  • Mice
  • Reverse Genetics
  • Rotavirus* / genetics
  • Viral Envelope Proteins / genetics

Substances

  • Viral Envelope Proteins
  • Glycoproteins
  • Immunoglobulin G
  • Antibodies, Viral

Supplementary concepts

  • Rotavirus D